Alzheimer's & Dementia: The Journal of the Alzheimer's Association

Slides:

Advertisements

Similar presentations

NEUROBIOLOGY ACTIVITY 2&3 POSITRON EMISSION TOMOGRAPHY (PET) IMAGES.

Advertisements

2015 Alzheimer's disease facts and figures Alzheimer's & Dementia: The Journal of the Alzheimer's Association Volume 11, Issue 3, Pages (March.

DIAGNOSTIC ACCURACY AND CONFIDENCE IN THE CLINICAL DETECTION OF COGNITIVE IMPAIRMENT IN EARLY-STAGE PARKINSON’S DISEASE Kathryn A. Wyman-Chick, Phillip.

Discriminatory and predictive capabilities of enzyme-linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer’s disease study Wesley.

Volume 3, Issue 1, Pages (January 2017)

Clinical and genetic analyses of familial and sporadic frontotemporal dementia patients in Southern Italy Rosa Capozzo, Celeste Sassi, Monia B. Hammer,

Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer's disease Bruno Dubois, Marie Chupin, Harald Hampel, Simone Lista,

Different pathways to Alzheimer’s disease

Flora H. Duits, Niels D. Prins, Afina W. Lemstra, Yolande A. L

Delayed-onset dementia after stroke or transient ischemic attack

Alzheimer's & Dementia: The Journal of the Alzheimer's Association

The differential diagnosis of amnestic mild cognitive impairment and Alzheimer's disease dementia by hippocampal volume measurement with MR in a chinese.

Localization of Hippocampal atrophy in Alzheimer's disease

Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design Arno de Wilde, Ingrid S. van Maurik, Marleen Kunneman, Femke Bouwman, Marissa.

Neurobiology Activity 2&3

Alzheimer's & Dementia: The Journal of the Alzheimer's Association

Christine Bredfeldt, Kristen Rice, Lisa Alecxih

Alzheimer's & Dementia: The Journal of the Alzheimer's Association

Alzheimer's & Dementia: The Journal of the Alzheimer's Association

Plasma nutrient status of patients with Alzheimer's disease: Systematic review and meta-analysis Sofia Lopes da Silva, Bruno Vellas, Saskia Elemans,

The global prevalence of dementia: A systematic review and metaanalysis Martin Prince, Renata Bryce, Emiliano Albanese, Anders Wimo, Wagner Ribeiro, Cleusa.

A multinational study distinguishing Alzheimer's and healthy patients using cerebrospinal fluid tau/Aβ42 cutoff with concordance to amyloid positron emission.

Alzheimer's & Dementia: The Journal of the Alzheimer's Association

Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment Sanna-Kaisa Herukka,

Alzheimer's & Dementia: The Journal of the Alzheimer's Association

Alzheimer's & Dementia: The Journal of the Alzheimer's Association

Imaging AD Progression Amyloid Imaging Agents.

Erosion of lumbar vertebral bodies from a chronic contained rupture of an abdominal aortic pseudoaneurysm W. Andrew Oldenburg, MD, Tariq Almerey, MD

Amyloid Imaging for Alzheimer's Disease in Practice

Paraneoplastic Opsoclonus-Myoclonus Syndrome as a New and Single Manifestation of Relapsing Disease in a Patient with Small Cell Lung Cancer Ernest Nadal,

Plasma nutrient status of patients with Alzheimer's disease: Systematic review and meta-analysis Sofia Lopes da Silva, Bruno Vellas, Saskia Elemans,

J Bordes, P.E. Gaillard, G Lacroix, B Palmier

Mika Kivimäki, Ritva Luukkonen, G. David Batty, Jane E

When is it Best to Repeat a 2-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography/Computed Tomography Scan on Patients with Non-Small Cell Lung Cancer.

Ara S. Khachaturian, David P

C. P. Bleeker-Rovers, A. Warris, J. P. H. Drenth, F. H. M. Corstens, W

Erosion of lumbar vertebral bodies from a chronic contained rupture of an abdominal aortic pseudoaneurysm W. Andrew Oldenburg, MD, Tariq Almerey, MD

Tharick A. Pascoal, Sulantha Mathotaarachchi, Monica Shin, Andrea L

Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups.

Prevalence and incidence of clinically diagnosed Alzheimer's disease dementia from 1994 to 2012 in a population study Kumar B. Rajan, Jennifer Weuve,

Clifford R. Jack, Heather J. Wiste, Stephen D. Weigand, Terry M

Prevalence and incidence of clinically diagnosed Alzheimer's disease dementia from 1994 to 2012 in a population study Kumar B. Rajan, Jennifer Weuve,

Evaluation of diagnostic tests

[18F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer's disease: Specific detection of advanced phases of amyloid-β.

Longitudinal uncoupling of cerebral perfusion, glucose metabolism, and tau deposition in Alzheimer's disease Antoine Leuzy, Elena Rodriguez-Vieitez,

LIFESPAN OF ONE FOCUSED ULTRASOUND MEDIATED BLOOD-BRAIN BARRIER TREATMENT IN A MOUSE MODEL OF ALZHEIMER'S DISEASE Charissa Poon, Kullervo Hynynen Alzheimer's.

The influence of biological and technical factors on quantitative analysis of amyloid PET: Points to consider and recommendations for controlling variability.

Summary of the evidence on modifiable risk factors for cognitive decline and dementia: A population-based perspective Matthew Baumgart, Heather M. Snyder,

Early cost-utility analysis of general and cerebrospinal fluid-specific Alzheimer's disease biomarkers for hypothetical disease-modifying treatment decision.

A 22-single nucleotide polymorphism Alzheimer's disease risk score correlates with family history, onset age, and cerebrospinal fluid Aβ42 Kristel Sleegers,

Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study Osama Sabri, Marwan N. Sabbagh, John Seibyl, Henryk Barthel,

Shruti Mishra, Brian Andrew Gordon, Karl A

Comparison of visual and quantitative florbetapir-PET reads in subjects with early Alzheimer's disease for assessing amyloid burden Bradley Wyman, Yahong.

Alzheimer's & Dementia: The Journal of the Alzheimer's Association

The incremental diagnostic value of 18F-florbetapir imaging in naturalistic patients with cognitive impairment: The India-FBP study Marina Boccardi,

Linus Jönsson, Pei-Jung Lin, Ara S. Khachaturian

Added value of 11C-PiB-PET imaging in the diagnosis of Alzheimer's disease Kristian Frederiksen, Anne-Mette Hejl, Ian Law, Steen Hasselbalch, Gunhild.

MR-less cortical surface-projection of PET images from 11C- and 18F-labeled radiotracers Vincent Doré, Pierrick Bourgeat, Luping Zhou, Jurgen Fripp,

Alzheimer's & Dementia: The Journal of the Alzheimer's Association

GREY MATTER CONNECTIVITY IS ASSOCIATED WITH CLINICAL PROGRESSION IN NON-DEMENTED, AMYLOID POSITIVE PATIENTS Betty M. Tijms, Mara ten Kate, Sander C.J.

Cerebral hypoperfusion is not associated with an increase in amyloid β pathology in middle-aged or elderly people Oskar Hansson, Sebastian Palmqvist,

Alzheimer's & Dementia: The Journal of the Alzheimer's Association

Intersite variability of CSF Alzheimer’s disease biomarkers in clinical setting Julien Dumurgier, Olivier Vercruysse, Claire Paquet, Stéphanie Bombois,

Different pathways to Alzheimer’s disease

Fig. 2. Correlation between Aβ42 and Aβ40 levels in iNPH, AD, and CN subjects. The scatter plot shows the correlation between Aβ42 and Aβ40 levels. Representative.

Alzheimer's & Dementia: The Journal of the Alzheimer's Association

Suzanne E. Schindler, Julia D. Gray, Brian A

Racial and ethnic estimates of Alzheimer's disease and related dementias in the United States (2015–2060) in adults aged ≥65 years Kevin A. Matthews,

Increased risk for dementia both before and after stroke: A population-based study in women followed over 44 years Xinxin Guo, Svante Östling, Silke.

Michael Navitsky, Abhinay D. Joshi, Michael D. Devous, Michael J

Presentation transcript:

Alzheimer's & Dementia: The Journal of the Alzheimer's Association Added value of 18F-florbetaben amyloid PET in the diagnostic workup of most complex patients with dementia in France: A naturalistic study Mathieu Ceccaldi, Thérèse Jonveaux, Antoine Verger, Pierre Krolak-Salmon, Claire Houzard, Olivier Godefroy, Trevor Shields, Audrey Perrotin, Rossella Gismondi, Santiago Bullich, Aleksandar Jovalekic, Nicola Raffa, Florence Pasquier, Franck Semah, Bruno Dubois, Marie-Odile Habert, David Wallon, Mathieu Chastan, Pierre Payoux, Andrew Stephens, Eric Guedj Alzheimer's & Dementia: The Journal of the Alzheimer's Association DOI: 10.1016/j.jalz.2017.09.009 Copyright © 2017 The Authors Terms and Conditions

Fig. 1 Patient disposition and subgroups. ∗All patients who received florbetaben, had a PET/computed tomography image, and in whom etiology of symptoms remained unexplained after a complete diagnostic workup. ∗∗Two subjects who refused lumbar puncture were also contraindicated for the procedure. Abbreviation: PET, positron emission tomography. Alzheimer's & Dementia: The Journal of the Alzheimer's Association DOI: (10.1016/j.jalz.2017.09.009) Copyright © 2017 The Authors Terms and Conditions

Fig. 2 Etiology of 137 patients with a change in diagnosis after positron emission tomography (PET) scan. Etiology was defined based on level-1 hypothesis of initial diagnosis (gray) and final diagnosis (colored). The data set included 76 subjects with positive PET and 61 subjects with a negative PET; not all changes are based on a level-1 change. Abbreviations: AD, Alzheimer's disease; ND, neurodegenerative; non-AD, neurodegenerative non-Alzheimer's disease; mixed, mixed dementia. Alzheimer's & Dementia: The Journal of the Alzheimer's Association DOI: (10.1016/j.jalz.2017.09.009) Copyright © 2017 The Authors Terms and Conditions

Fig. 3 Diagnostic confidence before and after florbetaben positron emission tomography (PET) and change in diagnostic confidence (per-protocol population). Alzheimer's & Dementia: The Journal of the Alzheimer's Association DOI: (10.1016/j.jalz.2017.09.009) Copyright © 2017 The Authors Terms and Conditions